FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3159843639> ?p ?o ?g. }

• W3159843639 abstract "Abstract Introduction: Androgen deprivation therapy (ADT) decreases bone mineral density and increases osteoporotic fracture (OsteoFx) risk. Hypothesis: To assess OsteoFx clinical risk factors (CRF) most predictive of future OsteoFx among men with prostate cancer on ADT. Methods: 4370 electronic medical records were reviewed of adult men with prostate cancer on cancer therapy +/- anti-osteoporosis therapy (Anti-OsteoRx) from 2011–2019. Cancer therapy included ADT (anti-androgens, GnRH agonists & antagonists, orchiectomy) and supplemental cancer therapy (SupplRx) (prostatectomy, brachytherapy, radiation, immunotherapy, and chemotherapy). Anti-OsteoRx included bisphosphonates, denosumab, and parathyroid hormone analogs. Patients with other cancers within 5 years of initial visit, metastasis, and traumatic fractures were excluded. Retrospective analysis was done to determine baseline characteristics, type and duration of ADT, Anti-OsteoRx, SupplRx, and osteoporosis CRF. Results: 615 men on ADT +/- SupplRx +/- Anti-OsteoRx were included in the study. 10.08% had OsteoFx irrespective of SupplRx or Anti-OsteoRx. Comparing the OsteoFx group to the non-fracture group, the following CRF were found to be statistically significant (p &lt;0.05): age at prostate cancer diagnosis (75.10 +/- 11.80 vs 71.59 +/- 9.80 y), diabetes mellitus (DM) (33.9 vs 19%), pre-existing comorbidities affecting bone (PreCo) (41.9 vs 24.8%), steroid use (11.3 vs 4.0%), and anti-convulsant and proton-pump inhibitor (med) use (45.2 vs 26.8%). 9.89% of 374 men on ADT only without (wo) Anti-OsteoRx fractured. Statistically significant CRF for OsteoFx were age (76.86 +/- 10.55 vs 73.02 +/- 10.06 y), DM (40.5 vs 19.6%), PreCo (45.9 vs. 26.4%), and med use (48.6 vs. 25.5%). In the following subgroups there were no statistically significant difference in CRF:•7.64% of 170 men on ADT + SupplRx wo Anti-OsteoRx •19.23% of 52 men on ADT only + Anti-OsteoRx •10.52% of 19 men on ADT + SupplRx + Anti-OsteoRx To increase statistical power, patients on ADT +/- SupplRx were assessed:•Among 71 men on ADT +/- SupplRx + Anti-OsteoRx, there were no statistically significant differences in CRF•Among the 544 men on ADT +/- SupplRx wo Anti-OsteoRx, significant CRF for OsteoFx were age (75.16 + 11.70 vs 71.37 + 9.85 y), DM (38 vs 19.4%), PreCo (38 vs 24.1%), steroid use (12 vs 3.8%), and med use (48 vs 24.3%) Discussion: Men with prostate cancer requiring ADT have a higher incidence of osteoporosis defined by DXA prior to initiating ADT compared to age-matched cohorts (Hussain et al). Our study revealed ADT with CRF is associated with OsteoFx irrespective of SupplRx or Anti-OsteoRx. Limitations include inability to evaluate efficacy of Anti-OsteoRx due to insufficient power. Conclusion: OsteoFx risk assessment utilizing CRF, FRAX, DXA with timely intervention may prevent OsteoFx in these high-risk patients." @default.
• W3159843639 created "2021-05-10" @default.
• W3159843639 creator A5014730347 @default.
• W3159843639 creator A5044829086 @default.
• W3159843639 creator A5050784244 @default.
• W3159843639 creator A5054949258 @default.
• W3159843639 creator A5063565461 @default.
• W3159843639 creator A5068923930 @default.
• W3159843639 date "2021-05-01" @default.
• W3159843639 modified "2023-09-23" @default.
• W3159843639 title "Clinical Risk Factors for Osteoporotic Fractures in Men With Non-Metastatic Prostate Cancer on Androgen Deprivation Therapy With or Without Anti-Osteoporosis Treatment" @default.
• W3159843639 doi "https://doi.org/10.1210/jendso/bvab048.495" @default.
• W3159843639 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8090090" @default.
• W3159843639 hasPublicationYear "2021" @default.
• W3159843639 type Work @default.
• W3159843639 sameAs 3159843639 @default.
• W3159843639 citedByCount "0" @default.
• W3159843639 crossrefType "journal-article" @default.
• W3159843639 hasAuthorship W3159843639A5014730347 @default.
• W3159843639 hasAuthorship W3159843639A5044829086 @default.
• W3159843639 hasAuthorship W3159843639A5050784244 @default.
• W3159843639 hasAuthorship W3159843639A5054949258 @default.
• W3159843639 hasAuthorship W3159843639A5063565461 @default.
• W3159843639 hasAuthorship W3159843639A5068923930 @default.
• W3159843639 hasBestOaLocation W31598436391 @default.
• W3159843639 hasConcept C121608353 @default.
• W3159843639 hasConcept C126322002 @default.
• W3159843639 hasConcept C126894567 @default.
• W3159843639 hasConcept C143998085 @default.
• W3159843639 hasConcept C2776286101 @default.
• W3159843639 hasConcept C2776541429 @default.
• W3159843639 hasConcept C2777899217 @default.
• W3159843639 hasConcept C2780192828 @default.
• W3159843639 hasConcept C71924100 @default.
• W3159843639 hasConceptScore W3159843639C121608353 @default.
• W3159843639 hasConceptScore W3159843639C126322002 @default.
• W3159843639 hasConceptScore W3159843639C126894567 @default.
• W3159843639 hasConceptScore W3159843639C143998085 @default.
• W3159843639 hasConceptScore W3159843639C2776286101 @default.
• W3159843639 hasConceptScore W3159843639C2776541429 @default.
• W3159843639 hasConceptScore W3159843639C2777899217 @default.
• W3159843639 hasConceptScore W3159843639C2780192828 @default.
• W3159843639 hasConceptScore W3159843639C71924100 @default.
• W3159843639 hasLocation W31598436391 @default.
• W3159843639 hasLocation W31598436392 @default.
• W3159843639 hasOpenAccess W3159843639 @default.
• W3159843639 hasPrimaryLocation W31598436391 @default.
• W3159843639 hasRelatedWork W13127835 @default.
• W3159843639 hasRelatedWork W15276436 @default.
• W3159843639 hasRelatedWork W16043632 @default.
• W3159843639 hasRelatedWork W16736519 @default.
• W3159843639 hasRelatedWork W17055214 @default.
• W3159843639 hasRelatedWork W17671018 @default.
• W3159843639 hasRelatedWork W18970280 @default.
• W3159843639 hasRelatedWork W19733631 @default.
• W3159843639 hasRelatedWork W20046256 @default.
• W3159843639 hasRelatedWork W3942566 @default.
• W3159843639 isParatext "false" @default.
• W3159843639 isRetracted "false" @default.
• W3159843639 magId "3159843639" @default.
• W3159843639 workType "article" @default.